CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0205 (clinicaltrials.gov NCT No: NCT01575925)
Title:A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION
Principal Investigator:Jatin J. Shah
Treatment Agent:Dexamethasone; Pomalidomide
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest tolerated dose
of pomalidomide that can be given in combination with dexamethasone in relapsed
or refractory MM. In addition, researchers will look at the drug dynamics of
pomalidomide in patients with kidney failure. The safety of this drug
combination will also be tested.

Pomalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Dexamethasone
Pomalidomide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Celgene Corporation
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults